2020
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomesSafety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy
Gonzales P, Grieco A, White E, Ding R, Ignacio RB, Pinto-Santini D, Lama JR, Altice FL, Duerr A. Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy. PLOS ONE 2020, 15: e0228433. PMID: 32134956, PMCID: PMC7058313, DOI: 10.1371/journal.pone.0228433.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAntiretroviral therapyClinical adverse eventsAdverse eventsTransgender womenUse disordersDouble-blind randomized placebo-controlled trialMSM/transgender womenRandomized placebo-controlled trialART-naïve participantsPossibility of hepatotoxicityPlacebo-controlled trialSerious adverse eventsHIV-positive menMedication-assisted therapyProportion of subjectsAdverse event dataMultiple new medicationsOral naltrexoneStudy medicationTransaminase elevationPlacebo armNTX treatmentTreatment armsNew medications
2017
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderFirst heavy drinking dayExtended-release naltrexoneXR-NTXDrinking daysPlacebo groupAlcohol consumptionDrinks/drinking dayPlacebo-controlled trialSerious adverse eventsDrinks/daySignificant differencesMonthly injectionsAdverse eventsHIV diseaseHIV outcomesTreatment armsAlcohol scoresMAIN OUTCOMEAlcohol consumption scoresUse disordersImprovement scoresDrinking outcomesNaltrexone
2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Annals Of Internal Medicine 2016, 165: 625-634. PMID: 27537841, DOI: 10.7326/m16-0816.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntiviral AgentsBenzofuransBuprenorphineBuprenorphine, Naloxone Drug CombinationDouble-Blind MethodDrug CombinationsDrug Resistance, ViralFemaleGenotypeHepatitis C, ChronicHumansImidazolesMaleMedication AdherenceMethadoneMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersQuinoxalinesRecurrenceSubstance Abuse, IntravenousYoung AdultConceptsDeferred-treatment groupOpioid agonist therapyImmediate treatment groupHepatitis C virus infectionC virus infectionElbasvir-grazoprevirDrug useProbable reinfectionAgonist therapyHCV infectionViral recurrenceAdverse eventsVirus infectionChronic HCV genotype 1Double-blind trialGenotype 3 infectionTreatment-naive patientsHCV genotype 1Interferon-free HCV treatmentOngoing drug useVirologic responseHCV therapyHCV treatmentPrimary outcomeGenotype 1
2013
High rates of police detention among recently released HIV-infected prisoners in Ukraine: Implications for health outcomes
Izenberg JM, Bachireddy C, Soule M, Kiriazova T, Dvoryak S, Altice FL. High rates of police detention among recently released HIV-infected prisoners in Ukraine: Implications for health outcomes. Drug And Alcohol Dependence 2013, 133: 154-160. PMID: 23769160, PMCID: PMC3786010, DOI: 10.1016/j.drugalcdep.2013.05.018.Peer-Reviewed Original ResearchConceptsOpioid substitution therapyAntiretroviral therapyHIV transmissionHIV epidemicHigh-risk injection practicesSignificant independent correlatesMedication interruptionOST treatmentART prescriptionAdverse eventsSubstitution therapyIndependent correlatesWithdrawal symptomsMale genderEssential medicationsInjection practicesHealth outcomesLogistic regressionHIVPublic healthTherapyHigh rateHealthCorrelatesParticipants
2010
Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment
Springer SA, Chen S, Altice FL. Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment. Journal Of Urban Health 2010, 87: 592-602. PMID: 20177974, PMCID: PMC2900572, DOI: 10.1007/s11524-010-9438-4.Peer-Reviewed Original ResearchConceptsOpioid agonist therapySubstance abuse treatment outcomesTreatment outcomesNon-detectable viral loadOpioid treatment outcomesBuprenorphine/naloxoneDSM-IV criteriaAgonist therapyAntiretroviral therapyCD4 countOpioid cravingAdverse eventsBuprenorphine treatmentOpioid dependenceViral loadUrine testingHIVTherapyVulnerable populationsWeeksOutcomesNLXTrialsInductionLikert scale